NCT05673109View on ClinicalTrials.gov

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 22, 2023

Primary Completion Date

October 8, 2023

Study Completion Date

October 8, 2023

Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
DRUG

AC176

AC176 will be given orally (PO) on a 28-day cycle.

Trial Locations (5)

Unknown

Site 2001, Beijing

Site 2003, Guangzhou

Site 2004, Hunan

Site 2005, Nanchang

Site 2002, Shanghai

Sponsors
All Listed Sponsors
lead

Accutar Biotechnology Inc

INDUSTRY

NCT05673109 - A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter